Elicio Therapeutics

OverviewSuggest Edit

Elicio Therapeutics is an immuno-oncology company, engineering therapies for cancer-killing immune responses. The Company is engineering potent cancer vaccines and immunotherapies for an array of aggressive solid and hematologic cancers. Elicio operates Amphiphile, a platform which enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body’s own system of immune defenses, with the aim to achieve durable cures.

TypePrivate
Founded2018
HQCambridge, MA, US
Websiteelicio.com

Latest Updates

Employees (est.) (Jan 2021)26(+14%)
Cybersecurity ratingAMore

Elicio Therapeutics Office Locations

Elicio Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
One Kendall Square Building 300 Suite 201
Show all (1)

Elicio Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

Elicio Therapeutics total Funding

$63 m

Elicio Therapeutics latest funding size

$33 m

Time since last funding

a year ago

Elicio Therapeutics investors

Elicio Therapeutics's latest funding round in October 2019 was reported to be $33 m. In total, Elicio Therapeutics has raised $63 m
Show all financial metrics

Elicio Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Elicio Therapeutics Online and Social Media Presence

Embed Graph

Elicio Therapeutics Blogs

Elicio Announces Additions to Board of Directors

Elicio Therapeutics, a next generation immunotherapy company, has named Daphne Karydas, Chief Financial Officer at Syndax Pharmaceuticals and Carol Ashe, Chief Business Officer at the New York Genome Center, to its board of directors.   The post Elicio Announces Additions to Board of Directors appea…

Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting

Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity. The post Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting appeared first on Elicio.

Elicio Therapeutics VP of Research and Founding Scientist talk COVID19

We are thrilled to feature our VP of Research Pete DeMuth, and Elicio’s Founding Scientist Darrell Irvine, as a guest on Julian Adams, CEO of Gamida Cell, new podcast “Science Side by Side” where they discuss the development, approval and delivery of a vaccine to prevent #COVID19. The post Elicio Th…

Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19 in Combination with CD19 CAR T cells

Elicio Therapeutics, a next generation immuno-oncology company, today announced that it has established a collaboration with the Moffitt Cancer Center to characterize combination therapies pairing Elicio’s CD19 Amphiphile and a universal FITC Amphiphile with CD19 CAR T cells. The post Elicio Therape…

Elicio Therapeutics to discuss novel lymph node vaccine targeting seven key mKRAS mutations at RAS – Targeted Drug Discovery Summit in Vienna, Austria

Elicio Therapeutics, a next generation immuno-oncology company, today announced Peter DeMuth, PhD., Elicio Vice President of Research, will present “Targeting the Lymph Nodes to Enhance Mutant KRAS-Specific Vaccine Responses,” at the upcoming RAS-Targeted Drug Discovery Summit in Vienna, Austria, fr…

Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002

Elicio Therapeutics and Natera, Inc.(NASDAQ: NTRA) today announced their collaboration in a prospective, multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology therapeutic targeting KRAS mutations in the adjuvant setting for patients with pancreatic ductal adenocarcinoma (PDAC) who ha…
Show more

Elicio Therapeutics Frequently Asked Questions

  • When was Elicio Therapeutics founded?

    Elicio Therapeutics was founded in 2018.

  • How many employees does Elicio Therapeutics have?

    Elicio Therapeutics has 26 employees.

  • Who are Elicio Therapeutics competitors?

    Competitors of Elicio Therapeutics include DNAtriX, Dauntless Pharmaceuticals and Inhibitor Therapeutics.

  • Where is Elicio Therapeutics headquarters?

    Elicio Therapeutics headquarters is located at One Kendall Square Building 300 Suite 201, Cambridge.

  • Where are Elicio Therapeutics offices?

    Elicio Therapeutics has an office in Cambridge.

  • How many offices does Elicio Therapeutics have?

    Elicio Therapeutics has 1 office.